openPR Logo

Press Releases from P&S Intelligence - Pharmaceuticals (16 total)

Cyclin-Dependent Kinase Inhibitors Therapeutics Key Players Analysis - Merck, El …

The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development. CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation. Download report sample at: http://bit.ly/2eqiPu5 **Various collaborations for CDK inhibitors drug development Eli Lilly

Systemic Lupus Erythematosus Pipeline Analysis - Anthera Pharmaceuticals, Inc., …

The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development. Explore report sample at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis/report-sample Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues. The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the

Herpes Simplex Virus Infections Therapeutic - Pipeline Analysis, Clinical Trials …

The study analysed that the Herpes simplex virus infections pipeline comprises of 20 drug candidates in different stages of development. As per the findings of the research, most of the drug candidates are being developed to be administered by oral route. Explore report sample at: https://www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis/report-sample Many technologies are being developed that offer promising innovative treatments which can control the progression of Herpes simplex virus infections. The technologies include, but not limited to,

Japanese Encephalitis Therapeutics - Pipeline Analysis, Clinical Trials, Patent …

Japanese encephalitis is a viral infection that spreads by mosquito bites. The study analyzed that the Japanese encephalitis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development. Explore report sample at: https://www.psmarketresearch.com/market-analysis/japanese-encephalitis-therapeutics-pipeline/report-sample The companies developing drugs for the treatment of Japanese encephalitis are laying more emphasis on the drug candidates to be developed as vaccines, due to the promising results shown by these candidates the in the clinical development.

mTOR Inhibitors Therapeutics Pipeline - Analysis, Clinical Trials, Collaboration …

According to the research findings, most of the drug candidates that act as mTOR inhibitors are being developed as small molecules, further supported by the fact that small molecules have several advantages such as it can be manufactured with production rate higher than any other molecule types. Explore report sample at: https://www.psmarketresearch.com/market-analysis/mtor-inhibitors-therapeutics/report-sample The positive clinical results of mTOR inhibitors drug candidates is a key factor driving the pipeline growth. For instance, F.

Rectal Cancer Therapeutics Pipeline Review 2018 - Clinical Trials, Results, Grow …

Rectal cancer is a disease in which malignant (cancer) cells are formed in the tissues of the rectum. The rectum is the lower part of the colon that connects the large bowel to the anus. It starts at the end of the final segment of the colon and ends when it reaches the short, narrow passage leading to the anus. Adenocarcinomas or cancer in the epithelium, comprise the vast majority

Rhabdomyosarcoma Therapeutics Analysis 2018 - Clinical Trials, Designations, Col …

According to the research findings, most of the drug candidates for the treatment of RMS are being developed to be administered by the intravenous route. The main advantage associated with the intravenous route is that the drug can easily be entered into the bloodstream, or lymph vessels, resulting in high bioavailability of the drug in the body and quick onset of action of drug. Explore report sample at: https://www.psmarketresearch.com/market-analysis/rms-therapeutics-pipeline-analysis/report-sample Several companies are

Bronchiectasis Therapeutics Analysis - Clinical Trials & Results, Collaboration …

The study analysed that the Bronchiectasis therapeutics pipeline comprises approximately 13 drug candidates in different stages of development. Bronchiectasis is a condition in which damage to the airways causes them to widen and become flabby and scarred. The airways are tubes that carry air in and out of lungs. Bronchiectasis usually is the result of an infection or other condition that injures the walls of airways or prevents the airways

Hyperlipidemia Therapeutics Pipeline Review 2018 - Clinical Trials, Results, Des …

Hyperlipidemia refers to elevated amount of lipids and cholesterol in the bloodstream. The two major types of lipid abnormalities are characterized by either high blood levels of triglycerides (known as hypertriglyceridemia) or high blood cholesterol levels (known as hypercholesterolemia). Hyperlipidemia is often associated with increased risk of coronary heart disease and strokes. The study analyzed that hyperlipidemia therapeutics pipeline comprises 53 drug candidates in different stages of development. Explore report sample

Peanut Allergy Therapeutics Pipeline Review 2018 - Clinical Trials, Patents, Des …

Peanut allergy is one of the most common type of allergies caused by a legume, known as peanut. Peanut is an annual herbaceous plant that belongs to the family of legumes. Other examples of legumes that can cause the disease include lentils, peas, and soybeans. Peanut allergy can be unpredictable and life-threatening and can bring the body into shock (anaphylaxis). The study analyzed that peanut allergy therapeutics pipeline comprises approximately

Methicillin-resistant Staphylococcus Aureus Therapeutics Pipeline Analysis 2018

MRSA infection caused by specific "staph" bacteria that is often resistant to most of antibiotic treatments. S. aureus (SA) is listed as a ‘superbug’ by U.S. Centers for Disease Control and Prevention (CDC). MRSA can either be present harmlessly on the skin (colonization) or enter the body (e.g. through broken skin) and cause an infection. The study analyzed that MRSA infection therapeutics pipeline comprises approximately 52 drug candidates in different

Sarcopenia Therapeutics - Pipeline Review 2018, Clinical Trials, Results, Design …

The study analyzed that the sarcopenia therapeutics pipeline comprises of 13 drug candidates in different stages of development. Further, the analysis also states that the pipeline has around 15% of the drug candidates that are being developed as gene therapy. Explore report sample at: https://www.psmarketresearch.com/market-analysis/sarcopenia-therapeutics-pipeline-analysis/report-sample Novartis AG, and Regeneron Pharmaceuticals Inc., have one drug candidate each in the Phase II stage of development for the treatment of the disease. In December 2017,

Restless Legs Syndrome Therapeutics 2018 - Pipeline Analysis, Patents, Collabora …

The study analyzed that the restless leg syndrome therapeutics pipeline comprises of eight drug candidates in different stages of development. Explore report sample at: https://www.psmarketresearch.com/market-analysis/restless-legs-syndrome-therapeutics/report-sample Around 62% of the pipeline drug candidates are being developed as small molecule for the treatment of RLS. Hisamitsu Pharmaceutical Co., Inc. is in a process to conduct Phase III clinical trial on its developmental drug for the treatment of RLS. In September 2017, AXIM Biotechnologies Inc.

Hemochromatosis/Iron Overload Therapeutics 2018 - Pipeline Analysis, Clinical Tr …

According to the research findings, a majority of the drug candidates for the treatment of hemochromatosis are being developed to be administered by the subcutaneous route, which facilitates the absorption of the drug as iron chelator drugs such as deferoxamine, that are poorly absorbed from the gastrointestinal tract. Explore report sample at: https://www.psmarketresearch.com/market-analysis/iron-overload-therapeutics-pipeline/report-sample As of now, there are three marketed iron chelator drugs available for the treatment of hemochromatosis namely; Deferasirox, Deferoxamine

ER+ Breast Cancer Pipeline Analysis - Clinical Trials, Patent, Designation and C …

The study analyzed that the estrogen receptor positive breast cancer pipeline comprises approximately 74 drug candidates in different stages of development. Explore report sample at: https://www.psmarketresearch.com/market-analysis/estrogen-receptor-positive-breast-cancer-pipeline-analysis/report-sample Chipscreen Biosciences, Ltd. is using chemo genomics approach for the development of their drug candidates in ER+ breast cancer. The approach connects small molecule structures to disease targets and therapeutic functions to accelerate the discovery process by effectively comparing the molecular profiles of successful drugs, failed

OX-40 Receptor Agonist Therapeutics Analysis - Patent, Designation, Collaboratio …

The study analyzed that the OX-40 receptor agonist therapeutics pipeline comprises approximately nine drug candidates in different stages of development. OX-40 is a costimulatory receptor that binds to its only known ligand, OX-40L, initiating cellular signaling events required for full activation of T cells following their recognition of a foreign antigen. OX-40 agonists mimic the effect of OX-40L, and boost the OX-40 signaling, and thereby leads to the suppression of

Go To Page:   1 2 3 4 5 6 7 8 9 10